Alterity therapeutics: appendix 4c – q1 fy26 quarterly cash flow report

Highlights new analysis of ath434-201 double blind trial strengthens efficacy signal at high dose level positive data from ath434-202 open-label trial demonstrates similar treatment effect in advanced msa as observed in earlier stage patients in double-blind study independent commercial assessment indicates usd $2.4 billion dollar potential worldwide peak sales opportunity in msa for ath434 cash balance on 30 september 2025 of a$54.56m melbourne, australia and san francisco, oct. 31, 2025 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its appendix 4c quarterly cash flow report and update on company activities for the quarter ending 30 september 2025 (q1 fy26). “as we near the end of the calendar year, i am very proud of all we have accomplished in 2025, led by our compelling clinical results in multiple system atrophy (msa), and i am excited about the prospect of delivering ath434 to the msa community,” said david stamler, m.d.
MSA Ratings Summary
MSA Quant Ranking